×

RNS Number : 2123Z

Pennant International Group PLC

13 March 2017

 

 

 

13 March 2017

 

 

PENNANT INTERNATIONAL GROUP PLC

(AIM: PEN)

 

Canadian contract amendment adds further £2million to Order Book

 

Pennant International Group plc ("Pennant" or "the Group"), the AIM quoted supplier of integrated support solutions, products and services, principally to the defence, rail, aerospace and naval sectors and to Government Departments, is pleased to announce that Public Services and Procurement Canada ("PSPC") has amended a contract with Pennant Canada Limited in Ottawa, Ontario, Canada. The amendment adds an additional C$3.8 million (£2.3 million) in contract value to the existing services consulting contract to September 2018.

 

The contract allows for provision of a range of services to the Canadian Department of National Defence ("DND") to optimize the use and effectiveness of Pennant's OmegaPS suite of supportability software products in use throughout DND.

 

The contract amendment allows for additional services to "be called upon as and when required by the customer".  The increased funding will predominantly impact performance in 2018 and increases the Group's order book by in excess of £2 million.

 

Philip Walker, Chief Executive of Pennant stated: "This increase in the contract ceiling serves as an important step in ensuring that the Department of National Defence derives maximum benefit from the use of the OmegaPS software suite."

Contacts:
Pennant International Group plc	www.pennantplc.co.uk
Philip Walker, CEO	+44 (0) 1452 714 914
WH Ireland Limited	www.wh-ireland.co.uk
Mike Coe / Ed Allsopp	+44 (0) 117 945 3470
Walbrook PR (Financial PR)	www.walbrookpr.com
Paul Vann / Tom Cooper	+ 44 (0)20 7933 8780 +44 (0)7768 807631

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

CNTUUVWRBUAOAAR

Close

×

RNS Number : 0853Z

Midatech Pharma PLC

10 March 2017

 

 

 

 

10 March 2017

Midatech Pharma PLC

("Midatech" or the "Company")

 

 

Midatech Announces Successful Initial Scale-Up of Its Sustained Release Manufacturing Facility

 

~ Q-Octreotide will become Midatech's first Sustained Release product candidate manufactured in house at its state-of-the-art facility in Bilbao, Spain ~

 

 

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology, is pleased to announce the successful initial scale-up and regulatory inspection of its state-of-the-art manufacturing site in Bilbao, Spain.

 

The manufacturing facility currently produces all Midatech's gold nanoparticle (GNP) products.  Now in addition the Company has installed facilities, equipment and quality assurance systems for in-house manufacturing of its Sustained Release (Q-Sphera) products, at scale.

 

This new facility has been successfully inspected by the Spanish Agency of Medicines and Medical Devices (AEMPS), and a formal Sustained Release sterile manufacturing licence will be granted upon completion of final process validation which is currently underway.

 

The first sustained release product to be produced at the Bilbao facility is anticipated to be Q-Octreotide (MTD201), Midatech's in-development programme for the treatment of acromegaly and carcinoid syndrome, which is planned to commence a Phase I study and follow-on regulatory program later in 2017, with anticipated approval and launch expected in 2018/19.

 

Commenting on the announcement, Dr. Jim Phillips, Chief Executive Officer of Midatech Pharma said: "We are pleased with the successful scale-up of our Bilbao facility which was completed within budget, and has had a positive inspection and debrief by the AEMPS.  Manufacturing our GNP and sustained release technologies in Bilbao allows us to control the process without being reliant on an external manufacturer, and all the investment, intellectual property and expertise will therefore be retained in-house. Furthermore, there will be significant cost efficiencies rather than outsourcing the manufacturing process to a third-party. This facility will provide for our requirements through to product launch, following which further scale up is planned to cover commercial supplies."

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

 

– Ends –

 

For more information, please contact:

 

Midatech Pharma PLC

Jim Phillips, CEO

Tel: +44 (0)1235 841575

www.midatechpharma.com

 

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Corporate Finance

Freddy Crossley / Duncan Monteith

Broking

Tom Salvesen

Tel: +44 (0)20 7886 2500

 

Consilium Strategic Communications (Financial PR)

Mary Jane Elliott / Ivar Milligan / Cameron Standage

Tel: +44 (0)20 3709 5700

Email: midatech@consilium-comms.com

 

Westwicke Partners (US Investor Relations)

Chris Brinzey

Tel: +1 339 970 2843

Email: chris.brinzey@westwicke.com

 

Notes for Editors

 

About Midatech Pharma PLC

Midatech is an international specialty pharmaceutical company focused on oncology and other therapeutic areas with a US commercial operation marketing four cancer care supportive products, and co-promoting two others. Midatech's strategy is to internally develop oncology products and collaborate with partners in other therapy areas, and to drive growth both organically and through strategic acquisitions. The Company's R&D activities are supported by two breakthrough drug delivery technologies: Q-Sphera for sustained release and our proprietary gold nanoparticles. The Group, listed on AIM: MTPH and Nasdaq: MTP, employs c.110 staff in four countries. For further company information see: www.midatechpharma.com

 

Forward-Looking Statements

Certain statements in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States, including (without limitation) those regarding potential offering of securities, the Group's financial position, business strategy, products, plans and objectives of management for future operations, and any statement preceded or followed by, or including, words such as "target", "believe", "expect", "aim", "intend", "will", "may", "anticipate", "would" or "could", or negatives of such words. Any forward-looking statements are based on currently available competitive, financial and economic data together with management's views and assumptions regarding future events and business performance as of the time the statements are made and are subject to risks and uncertainties. We wish to caution you that there are some known and unknown factors that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements.

 

Reference should be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

UPDDBGDXLSGBGRC

Close

×

Neville Registrars is delighted to welcome Microsaic Systems plc as the newest addtion to its list of client companies.

Microsaic Systems is a high technology company developing and marketing chip-based mass spectrometry (MS) instruments. The Company was established in 2001 to develop miniaturised MS instruments based on Micro-Electro-Mechanical Systems (MEMS) technology originating at the highly regarded Optical and Semiconductor Devices Group at Imperial College London.

The Company has been based at headquarters in Woking, UK since September 2004 and was admitted to AIM, a market of the London Stock Exchange, in April 2011

Further information can be found on the Company's website: http://www.microsaic.com/

Close

×

RNS Number : 7467Y

Genedrive PLC

08 March 2017

 

For release: 8th March 2017

 

genedrive plc ("genedrive" or the "Company")

 

 

Successful Clinical Results for Genedrive® HCV Assay

 

External Validation Studies Show Sensitivity of greater than 99% and Specificity of 100% for Hepatitis C Assay Designed for Decentralised Use in Resource Limited Settings

 

 

genedrive plc, the near patient molecular diagnostics company, today announces that it has successfully completed clinical validation studies to support a submission for CE regulatory approval of its Genedrive® HCV ID Kit.

 

The studies, performed at Institut Pasteur, Paris, and Queen's Medical Centre, Nottingham, demonstrated an overall sensitivity of greater than 99% and specificity of 100% over a 955 sample cohort, comparing the test to the Abbott Molecular RealTime HCV Viral Load Assay. The Genedrive® HCV ID Kit sensitivity, specificity, and limit of detection meet the Target Product Profile specifications for decentralised use in resource limited settings, as outlined by the Foundation for Innovation in Diagnostics (FIND). The validation studies were supported by the European Commission FP7 PoC-HCV programme.

 

The HCV test is performed on the Company's Genedrive® portable molecular diagnostics platform, designed for use at the point of need. The assay uses only a small amount of human plasma (25ul), eliminating the need for a separate RNA viral extraction process, and yields results within 90 minutes.

 

"Recently approved direct acting antiviral therapies have revolutionised therapeutic options for treating HCV patients, however the challenge remains to identify infected persons, many of whom are living in geographic regions that lack access to state-of-the-art diagnostics," said Dr Darragh Duffy of the Institut Pasteur. "The Genedrive® HCV ID Kit is a rapid and simple to use point of need test that would enable real-time treatment and management of chronic HCV patients in decentralised settings."

 

"We are very pleased with the performance of the assay's sensitivity, specificity and speed. This presents the Genedrive® HCV test with the opportunity to be the first to market as a decentralised, qualitative, molecular HCV test," said David Budd, Chief Executive Officer of genedrive plc. "WHO HCV testing guidelines recommend the initiation of treatment with direct acting antiviral agents, following a qualitative or quantitative HCV molecular test. The Genedrive® HCV ID Kit is well placed to support the  goal of increasing access to HCV diagnostics in decentralised laboratories in resource limited settings."

 

The Company anticipates submission for CE certification under the EU Medical Devices Directive for Genedrive® HCV ID Kit by the end of March 2017. CE certification is a key step toward product commercialisation later this year.

 

–  Ends  –

 

 

For further details please contact:

genedrive plc

David Budd: CEO                                                                                                              +44 (0)161 989 0245

Matthew Fowler: CFO

 

Peel Hunt LLP

James Steel                                                                                                                        +44 (0)207 418 8900

Oliver Jackson

 

Consilium Strategic Communications

Chris Gardner                                                                                                                    +44 (0)203 709 5700

Matthew Neal

Laura Thornton

genedrive@consilium-comms.com 

 

 

Notes to Editors

 

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and MTB/RIF assay has been launched in India.

 

Further details can be found at: www.genedriveplc.com and www.genedrive.com 

 

About Hepatitis C

Hepatitis C is an international public health challenge, comparable to other major communicable diseases, including HIV, tuberculosis and malaria. It is estimated that 150-200 million people, or approximately 3% of the world's population, are living with chronic hepatitis C, and more than 350,000 people die yearly from hepatitis C related diseases. In 2016, WHO published the first global health sector strategy on Hepatitis with a goal of eliminating viral hepatitis as a major public health threat by 2030. New oral, well-tolerated treatment regimens can achieve cure rates of over 90% however access to rapid, inexpensive and accurate diagnostics are a critical bottleneck that must be addressed to eradicate Hepatitis C.

 

Further details on the PoC-HCV project can be found at http://www.poc-hcv.eu/index.php 

 

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCOKODDDBKDDNK

Close

×

RNS Number : 5444Y

TLA Worldwide PLC

06 March 2017

 

6 March 2017

TLA Worldwide plc

 

("TLA" or the "Group")

 

TLA Baseball Offseason and Earn-out Update

 

TLA Worldwide plc (AIM: TLA), a leading athlete representation and sports marketing business, is pleased to report that its Baseball division has negotiated a total of $237m in offseason contracts, on behalf of its clients, (2016 offseason: $174m) to date which the Group expects to increase further as the offseason contract period comes to an end.  This is a record performance for the Baseball division and highlights its strong position following the investment made in 2016.  Offseason contracts are calculated before any performance based incentives which may be earned by TLA's Baseball clients in 2017 and beyond. 

 

TLA has also agreed to amend the earn-outs and extend the employment agreements (the "Agreements") for the principals of LS Legacy Sports LLC ("Legacy") and Peter E. Greenberg and Associates Ltd ("PEG") as described below. The Agreements were entered into on 4 March 2017.

 

TLA acquired the leading baseball representation businesses, Legacy and PEG, in December 2011 and November 2012, respectively, forming the Group's Baseball division.  Both entities are wholly owned subsidiaries of the Group and for the year ended 31 December 2015 the Baseball division generated operating income of $13.8m and headline EBITDA of $6.8m.

 

The original earn-outs with the principals of Legacy and PEG covered the five-year period following their acquisitions.  These have been replaced with amended and extended earn-out arrangements covering additional five-year periods. The payments to Legacy and PEG under these arrangements are payable in cash and conditional on the combined Baseball division achieving certain EBIT targets over the period up until 2021 for Legacy and 2022 for PEG.  Upon achievement of the escalating Baseball EBIT hurdles, the total consideration for the principals of Legacy and PEG under the earn-outs is capped at $7.2m.

 

As a result of the amendment and extension to the Legacy and PEG earn-outs, the total deferred consideration on the Group's balance sheet, which as at 30 June 2016 was $9.8m, is expected to increase by approximately $0.7m.

 

In addition, the Legacy and PEG employment extensions bring them in-line with the employment extensions agreed with the key principals of The Agency Sports Management which was acquired by the Group in 2011.  TLA has now extended its employment agreements with the principals of these three businesses who will remain at TLA for at least another five years.

 

Given the investment made to date and the resultant offseason activities, the Board believes that the Agreements are a positive development for the Group and will ensure that the Baseball principals remain incentivised and committed to deliver on the Baseball growth plans over the coming years.

 

Mike Principe, CEO of TLA, said: "The future success of our Baseball division is based on our investment in high quality people and we are excited about the prospects of this division having secured key personnel over the long term. The negotiation of at least $237m in offseason contracts is a record performance for TLA Baseball and this, combined with the right people in place for years to come, gives the Board confidence that the Baseball division is in a strong position to deliver on its growth plans."

 

Related party transaction

 

The Legacy principals, being Greg Genske, Brian Peters and Scott Parker, are deemed to be related parties under the AIM Rules and therefore their participation in the arrangements described above represent a related party transaction.

 

In accordance with AIM Rule 13, the Board of Directors (excluding Greg Genske who is a related party) consider, having consulted Numis (the Group's nominated adviser) that the terms of the transaction are fair and reasonable insofar as TLA's shareholders are concerned.

 

Enquiries:

 

TLA Worldwide
Bart Campbell, Executive Chairman Michael Principe, Chief Executive Officer	+1 212 645 2141
Numis Securities
Nick Westlake and Oliver Hardy (Nomad)	+44 20 7260 1000
Christopher Wilkinson (Broker)
Luther Pendragon
Harry Chathli, Alexis Gore	+44 20 7618 9100

 

About TLA Worldwide

 

TLA Worldwide is a leading athlete representation, event management and sports marketing group quoted on AIM-LSE in London. The Group derives revenues from long-term agency relationships with many prominent U.S. and international sports stars, broadcasters and media personalities associated with major sports including the MLB, NFL, NBA, PGA tour, AFL and Olympians and Cricketers. In addition, it also provides a range of services in respect of media consultancy, sports sponsorship and event creation and ownership, including the International Champions Cup tournament in Australia. TLA Worldwide serves its clients from 10 locations worldwide including its offices in London, UK; New York, Newport Beach and California, USA; Melbourne, Perth, Adelaide and Sydney, Australia. For more information, please visit www.tlaworldwide.com.

 

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCEANDSELFXEEF

Close

×

RNS Number : 6400Y

CML Microsystems PLC

06 March 2017

 

06 March 2017

CML Microsystems Plc

New Customer Announcement

CML Microsystems Plc, ("CML" or "the Group"), which designs, manufactures and markets mixed-signal and Radio Frequency (RF) semiconductors, primarily for global communication and solid state storage markets, is pleased to announce that its wholly owned subsidiary, Hyperstone GmbH, has today announced its first design-win with Micron Technology, Inc., a world leader in innovative memory solutions.

Hyperstone's USB 3.1 Flash Memory controller solution, U9, has been designed into Micron's new eU500 embedded USB module, an embedded solid state storage solution aimed at networking, telecoms and industrial Internet of Things (IoT) markets. The Micron product is being launched at the upcoming Embedded World Show in Nuremberg, Germany, from 14 – 16 March 2017.

Group Managing Director of CML Microsystems Plc, Chris Gurry, stated: "The combination of Hyperstone's latest flash memory controller and Micron's world leading NAND flash memory solution is a formidable one, leveraging the core strengths of each company. Hyperstone's U9 is compatible with current and next generation flash memory technologies whilst offering class-leading performance within demanding industrial application areas."

The full Hyperstone press release can be found at https://www.hyperstone.com

 

The full Micron press release can be found at http://investors.micron.com/releasedetail.cfm?ReleaseID=1015912

 

CML Microsystems Plc Chris Gurry, Group Managing Director Neil Pritchard, Group Financial Director	www.cmlmicroplc.com Tel: +44 (0)1621 875 500
Cenkos Securities plc Alex Aylen (Sales) Max Hartley (Corporate Finance)	Tel: +44 (0)20 7397 8900
SP Angel Corporate Finance LLP Jeff Keating	Tel: +44 (0)203 463 2260
Alma PR Josh Royston Robyn McConnachie	Tel: +44 (0)7780 901979 Tel: +44 (0)7540 706191

 

About CML Microsystems PLC

CML designs and develops semiconductors for the industrial storage and communications markets. The Group utilises a combination of in-house and outsourced manufacturing and has trading operations in Europe, the Far East and the USA. CML targets niche markets with strong growth profiles and high barriers to entry. It has secured a diverse, blue chip customer base, including some of the world's leading telecoms equipment providers and industrial product manufacturers.

The spread of its customers and products largely protects the business from the cyclicality usually associated with the semiconductor industry. Growth in its end-markets is being driven by factors such as the ever-increasing trend towards solid state storage devices in the commercial and industrial sectors, the upgrading of telecoms infrastructure around the world and the growing prevalence of private commercial communications networks for voice and/or data communications linked to the industrial internet of things (IIoT).

The Group is cash-generative, has no borrowings and is dividend paying.

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAXQLFBDXFXBBQ

Close

×

RNS Number : 2722Y

First Derivatives PLC

02 March 2017

 

2 March 2017

 

First Derivatives plc

("FD" or the "Group")

 

Contract Win

 

FD (AIM: FDP.L, ESM: FDP.I) announces that it has signed a contract with a Fortune 500 engineering solutions company for the use of its Kx technology within precision manufacturing. Kx has been selected as the high-performance, time-series data historian and analytics platform in the next version of the client's fault detection product range, expected to be released in mid-2017. The client expects the use of Kx to provide a competitive advantage in its market and has therefore asked not to be named at this stage.

 

The client is a leading supplier of precision fault detection solutions which enable its customers to increase productivity, improve quality and maximise manufacturing equipment efficiency. The fault detection solution takes readings from thousands of sensors providing rapid ingestion, complex event processing, and compares these readings to historical data to detect anomalies and potential faults. With increasing numbers of sensors and frequency of readings now taking place, the performance of the client's existing solution had become sub-optimal and, following a successful proof of concept, it has decided to replace it with Kx. Initial benchmarking shows that, by incorporating Kx, the product is capable of handling many millions of sensor reads per second, representing a significant change in the product's performance and scalability.  

 

FD will receive revenue as existing customers of the fault detection solution upgrade to the version powered by Kx. The total expected value over a five year period places this contract amongst some of the larger software contracts FD has signed.  In addition to the use of Kx within its fault detection solutions, the client has identified additional potential uses of Kx within its operations and FD is working with the client to develop these additional opportunities.

 

The use of Kx for fault detection is one application of the use of sensor data to aid efficiency within manufacturing, also known as the Industrial Internet of Things (IIoT). According to ABI Research, the addressable market for analytics and other value-added services for the IIoT is expected to reach $80-120 billion by 2018.

 

Brian Conlon, Chief Executive Officer of FD, commented: "This is a flagship contract win for Kx in the Industrial Internet of Things, secured through our ability to demonstrate higher performance, greater scalability, and lower total cost of ownership than competing solutions. We see considerable potential for Kx to establish itself as a market-leading solution for streaming analytics on sensor data, particularly within manufacturing environments."

 

For further information please contact:

First Derivatives plc Brian Conlon, Chief Executive Officer Graham Ferguson, Chief Financial Officer Ian Mitchell, Head of Investor Relations	+44(0)28 3025 2242 www.firstderivatives.com
Investec Bank plc (Nominated Adviser and Broker) Dominic Emery Carlton Nelson Sebastian Lawrence	+44 (0)20 7597 4000
Goodbody (ESM Adviser and Broker) Linda Hickey Finbarr Griffin	+353 1 667 0420
FTI Consulting Matt Dixon / Dwight Burden / Antonia Gray	+44 (0)20 3727 1000

 

About FD

FD is a global technology provider with 20 years of experience. The Group's Kx technology is used by some of the world's largest finance, technology and energy institutions. FD employs over 1,700 people worldwide and has operations in London, New York, Stockholm, Singapore, Hong Kong, Tokyo, Sydney, Palo Alto, Toronto, Philadelphia, Dublin, Belfast and its headquarters in Newry.

 

For further information, please visit www.firstderivatives.com

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

CNTEAKDFEFFXEFF

Close

×

RNS Number : 1419Y

Northern Petroleum PLC

01 March 2017

 

Northern Petroleum Plc

("Northern Petroleum" or "the Company")

Onshore Italy seismic programme

Northern Petroleum (AIM: NOP), the AIM quoted oil and gas company focusing on production led growth balanced with high impact exploration and appraisal opportunities, announces that Shell Italia E&P S.p.A ("Shell") has initiated a local engagement programme in relation to the Cascina Alberto permit, onshore northern Italy.

The programme is being undertaken in advance of the submission of an Environmental Impact Assessment ("EIA") necessary to conduct a geophysical survey. The programme includes up to 200 meetings with local authorities, communities and stakeholders to gather information and opinion to assist with the EIA submission. Field work for the seismic survey is expected to begin in 2018 following approval of the EIA. Northern Petroleum owns a 20 per cent. non-operated working interest and is carried for the seismic acquisition up to a gross cost of US$4 million.

Keith Bush, Chief Executive Officer of Northern Petroleum, commented:

"Shell have demonstrated great commitment in progressing this exploration opportunity, even during the recent industry downturn. The views of local stakeholders are important when planning any type of operational work and we support Shell's inclusive approach during the EIA process.

"Cascina Alberto represents an important part of the Company's strategy of creating three to four company changing events over the next few years, something that will enhance the value of the sustainable production growth in Canada."

 

The Cascina Alberto licence

The Cascina Alberto exploration permit covers an area of 462 square kilometres across the Piedmont and Lombardy regions.

The area was held in the late 1990s by ENI and was the subject of a farm-in by Enterprise Oil in 2000. The exploration focus was on a prospect which ENI had interpreted as holding 300 million barrels of prospective resource. The structure of the prospect was believed to be similar to the nearby Villafortuna-Trecate field, located 25 kilometres to the south east and one of the largest onshore oil fields discovered in western Europe, having produced in excess of 210 million barrels of oil to date.

Northern Petroleum was awarded the permit in July 2014 and, after being approached by Shell, completed the farm out in early 2015. Shell acquired 80 per cent. of the permit and operatorship for a cash consideration of US$850,000, a carry for seismic acquisition of up to US$4 million gross cost, a carry on an exploration well of up to US$50 million gross cost and a carry on all ongoing general and administrative costs.

-Ends-

 

For further information please contact:

Northern Petroleum Plc                                                                                                        Tel: +44 (0)20 7469 2900

Keith Bush, Chief Executive Officer

Nick Morgan, Finance Director

 

Stockdale Securities Limited (Nomad and Joint Broker)                                         Tel: +44 (0)20 7601 6100

Antonio Bossi

David Coaten

 

FirstEnergy Capital LLP (Joint Broker)                                                                              Tel: +44 (0)20 7448 0200

Jonathan Wright

 

Note to Editors:

Northern Petroleum is an oil and gas company focused on production led growth. The Company is undertaking a redevelopment and production project in north west Alberta and has a broader portfolio of exploration and appraisal opportunities in countries of relatively low political risk, primarily Italy. Comprehensive information on Northern Petroleum and its oil and gas operations, including press releases, annual reports and interim reports are available from Northern Petroleum's website: www.northernpetroleum.com

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCEADAPALFXEAF

Close

×

RNS Number : 9770X

SpaceandPeople PLC

28 February 2017

 

SpaceandPeople plc ("SpaceandPeople")

Promotional and MPK Contract with Primesight's Airport Portfolio

SpaceandPeople (AIM: SAL), the retail, promotional and brand experience specialist, is pleased to announce it has been awarded the exclusive rights to promote brands and manage promotional space across Primesight's airport portfolio in the UK.

SpaceandPeople now has the exclusive rights to promote brand activity across six major airports in the UK including London Gatwick, London Stanstead, Manchester and London Luton. This contract reinforces SpaceandPeople's position as Europe's biggest company selling experiential media.

As well as brand experience promotions, the contract will include the installation of several SpaceandPeople's Mobile Promotions Kiosks into airports for the first time.

 

Sarah Parkes – Managing Director – Primesight Airport said "We are delighted to be working with SpaceandPeople on our airport network. Their experience at major transit hubs including all the London Railway stations as well as their extensive geographic network of venue locations make them the perfect choice of partner for our prestigious portfolio of high footfall airports."

 

Matthew Bending – CEO – SpaceandPeople said "We are excited to be working with Primesight on their airport network. This will deliver key brand experiences and promotions which will complement the customer demographic and add further vibrancy to the airports."

 

 

Contact details:

 

SpaceandPeople Plc	0845 241 8215
Matthew Bending, Gregor Dunlay
Cantor Fitzgerald Europe	020 7894 7000
David Foreman, Will Goode (Corporate Finance)
David Banks, Alex Pollen (Sales)

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRABLGDDRXDBGRR

Close

×

RNS Number : 7346X

EU Supply PLC

24 February 2017

 

24 February 2017

EU Supply plc

("EU Supply", the "Company" or the "Group")

 

Grant award

 

EU Supply (LSE AIM: EUSP), the e-procurement software provider, is pleased to announce that it has been awarded a grant from the European Union for the development of additional features to its CTM™ platform (the "Grant").

 

The Grant is expected to be worth up to €120,000 and to be received during 2017. It has been awarded for the development of certain additional features to the Company's CTM™ platform in order to meet new legislative requirements in the EU/EEC countries.  

 

 

               

 

FURTHER ENQUIRIES

EU Supply PLC Tel: 020 7127 4545 Thomas Beergrehn, CEO   Mattias Ström, CFO       Stockdale Securities Tel: 020 7601 6100 Tom Griffiths, David Coaten

 

A copy of this announcement is available at www.eu-supply.com.

 

Notes to Editors

EU Supply is the UK holding company of the EU Supply Group, a Sweden-based e-commerce business, which has an established, market-leading, multilingual e-procurement platform for esourcing, e-tendering and contract management, tailored for the highly regulated European public sector market.

Since 2006, the Group has invested heavily in employing specialist programmers to add functionality, legal compliance as required and security features to its Complete Tender Management™ ("CTM™") platform to ensure that the Group is ideally placed to secure new contracts with EU Member States and their Contracting Authorities. The platform is available in 16 different languages.

The Directors believe that the Group's CTM™ platform is one of the easiest to use and most functionally advanced solutions available in the market. The CTM™ platform is used by over 7,000 European public sector bodies in 9 EU/EEC Member States and has National Procurement System status in four Member States (the UK, Ireland, Norway and Lithuania).

The Company's shares were admitted to trading on AIM in November 2013. In August and September 2015, the Company raised a total of £2.061m (before expenses) through a placing of new shares and the issue of first and second tranches of Convertible Loan Notes to institutional and other investors.

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRALLFITFIIVFID

Close